Get more info on this report!Hospital-Acquired Infections: Diagnostic Markets and TestingDevelopments, Treatments, Key Com...
Some of the issues discussed in this report include:      Development of Potential Life-Saving Products      Development o...
Becton Dickinson       Cepheid       Cubist       Daiichi Sankyo       Gen-Probe       GlaxoSmithKline       Johnson & Joh...
"Everyone is interested in faster tests and immediate results," added Carlson. "Although       the rate of infection wont ...
Infection Control Summary    Scope and Methodology    Total Size and Growth of the Market    Issues and Trends Affecting M...
The Elderly     Compromised Individuals     Measures for Reducing Resistance     Antibiotic Cycling     Antibiotic Educati...
Pseudomonas Aeruginosa            Staphylococcus Aureus            Tuberculosis            Urinary Tract Infections     Ne...
Cepheid     Cubist Pharmaceuticals     Daiichi Sankyo     Diatherix Laboratories Inc.     Gen-Probe Inc.     GlaxoSmithKli...
Table 3-2: MRSA Risk and Testing Priority     Table 3-3: Recent Approvals for Hospital Infection Testing (Product, Company...
UK +44.207.256.3920Intl: +1.240.747.3093Fax: 240.747.3004
Upcoming SlideShare
Loading in …5
×

Hospital-Acquired Infections: Diagnostic Markets and Testing Developments, Treatments, Key Competitors and Trends

1,465 views

Published on

Published in: Business, Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
1,465
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
15
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Hospital-Acquired Infections: Diagnostic Markets and Testing Developments, Treatments, Key Competitors and Trends

  1. 1. Get more info on this report!Hospital-Acquired Infections: Diagnostic Markets and TestingDevelopments, Treatments, Key Competitors and TrendsJuly 1, 2011A hospital-acquired infection (HAI)is a new infection that develops in a patient duringhospitalization. It is usually defined as an infection that is identified at least forty-eight toseventy-two hours following admission, so infections incubating, but not clinicallyapparent, at admission are excluded. This type of infection is also known as anosocomial infection (or more generically healthcare-associated infections).The following market data is provided in this report: Market for HAI Diagnostics Forecast for HAI Diagnostics to 2015 HAI Tests on the Market Market for Diagnostics by Infection Type (C. Diff., MRSA, Pneumonia, Other) Molecular HAI Market vs. Conventional HAI Market, Present and in 2015 Geographic Breakdown of Testing (U.S., Europe, Asia, ROW) New Hospital Infection Product Testing Products in the Market Company Profiles Treatment Products on the Market, HAI Antibiotic market Size and ForecastBoth diagnostics and treatment segments have unique circumstances for growth whichare discussed in detail in the report. Worldwide, both segments combined are worthmore than $9 billion for 2010 with 2015 sales expected to reach $10.3 billion. Themarket has shown an increase of 3% annually with sales increasing from $7.9 billion in2005. Although the treatment segment will continue to struggle to maintain growth, thetesting segment will offset declines beginning in 2012.This report primarily focuses on bacterial nosocomial infections with some mention ofviral infections. The major consideration is given to bacterial nosocomial infectionsbecause a) they are the most frequent type of infections spread in the hospital setting,and b) the practical aspects of diagnosis and therapy are more meaningful based bothon medical considerations and on market considerations.
  2. 2. Some of the issues discussed in this report include: Development of Potential Life-Saving Products Development of Fast Testing Systems Growing Drug Resistance Development of Better Pharmacodiagnostics Market Opportunity and Growth Rates Expected in Diagnostics versus Treatment Hospital Procedures for Use of Testing and Antibiotics Attention to Special Population Issues Demographics and Epidemiology New Government Guidelines and Requirements for Preventing Infection Focus on Alliances and PartnershipsMarket analysis in this report considers primarily the epidemiological considerations andthe size of patient groups both in the United States and globally, where available. Wehave accumulated the most recent data available, understanding that virtually noorganization does extensive studies on these applications on a regular basis. Manystudies are highly localized and may only apply to a community, state or country (moreoften countries that are not a part of the major markets for nosocomial diagnostic andtherapeutic products). In many instances, we have had to draw from broaderepidemiologic data, that is, on data that reach outside of the hospital environment inorder to try and construct a picture of the nosocomial testing and treatment needs.The primary focus of this report is on the bacterial form of nosocomial infections, andthose with significant impact on the hospital setting and markets. In looking at theseinfections, we consider the diagnostic and therapeutic technologies that are currentlyavailable and attempt to project trends in these product areas. To some extent, we arelimited by the activity of the industries associated with the diagnosis and treatment ofthese infections. For the most part, these activities are limited and the advancedtechnologies seen in other areas of medical application are not necessarily present interms of microbiology.The analysis presented in this report is based on data from a combination of company,government, industry, institutional and private sources. It includes information fromextensive literature reviews and discussions with experts in the field, includingmicrobiologists, pathologists, hospital authorities, research scientists, businessdevelopment managers and marketing managers.Companies profiled in this report are: Abbott Laboratories AdvanDX Alere AstraZeneca Bayer Schering Pharma
  3. 3. Becton Dickinson Cepheid Cubist Daiichi Sankyo Gen-Probe GlaxoSmithKline Johnson & Johnson Merck & Co. Meridien Pfizer Roche SeegeneAdditional InformationNew York, July 14, 2011-- When a Hospital-acquired infection (HAI) is suspected,hospitals need results quickly, which is good news for innovative diagnostic test makers,notes healthcare market research firm Kalorama Information. In its recent report,Hospital-Acquired Infections: Diagnostic Markets and Testing Developments,Treatments, Key Competitors and Trends, Kalorama predicts the combined worldmarket for testing and treatment products for HAI will reach $10.3 billion in 2015, upfrom $9 billion in 2010, with higher growth experienced in the testing segment.Kaloramas report finds nosocomial infections are an inherent part of any healthcaresystem and have a 5% infection rate of the 40 million hospital visits a year, causing100,000 deaths in the U.S. annually. In an effort to decrease the rate of fatality,hospitals are shifting focus towards rapid discovery and treatment of nosocomialinfections, driving sales of testing products."The growth opportunities are in testing," said Bruce Carlson, publisher of KaloramaInformation. "The treatment market is slowing down, with a little growth in the future,which will be dominated by established pharmaceutical companies."Specific nosocomial infections that are candidates for testing innovation, includePneumonia, which comprises nearly 20% of all HAIs with 300,000 cases annually andhas an associated mortality rate of 30-70%, as well as MRSA, which accounts for nearly20,000 deaths a year. According to Kalorama, 20-30% of these infections arepreventable through intensive hygiene and control programs and the remaining 70-80%through more involved measures, such as hospital architecture and air sanitation andthe use of disposable equipment and supplies.
  4. 4. "Everyone is interested in faster tests and immediate results," added Carlson. "Although the rate of infection wont change, quicker turnover will improve patient outcome and drive down mortality rates." Kalorama Informations report, Hospital-Acquired Infections: Diagnostic Markets and Testing Developments, Treatments, Key Competitors and Trends, reveals the world market for HAI diagnostic and treatment markets, providing segmented market data for molecular and conventional testing. It also covers the development of new testing systems and products and provides an analysis on growing drug resistance. More Infectious Diseases Reports by Kalorama Information Asian Vaccine Markets by Kalorama Information The Asian vaccine market is relatively small compared to its population, yet it is growing, and pharmaceutical manufacturers increasingly will look to boost sales from ... The Worldwide Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals) by Kalorama Information The anti-infective market is at a critical juncture. For the past 60 years, antibiotic drugs have turned bacterial infections into treatable conditions rather than ... Infectious Disease Diagnostic Markets by Kalorama Information The ubiquity of infections makes their detection a healthcare priority and an ongoing opportunity for IVD companies. The aging of the population, and emerging ... H1N1 (Swine Influenza) Market Assessment (Latest Data, Company Profiles, Implications for Immunoassays and Molecular Assays) by Kalorama Information The outbreak of H1N1 (swine flu) highlighted the public health importance of improved testing techniques and providing market opportunities for manufacturers of diagnostic tests ... Pharmaceutical Markets in India by Kalorama Information The pharmaceutical market in India ranks among the top twenty markets in the world with the potential to move up in ranking rather quickly. ... Table of ContentsTABLE OF CONTENTS CHAPTER ONE: EXECUTIVE SUMMARY Overview
  5. 5. Infection Control Summary Scope and Methodology Total Size and Growth of the Market Issues and Trends Affecting Market Molecular Testing vs. Conventional Testing Leading CompetitorsCHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDS Overview Introduction to Pathogens Classification of Antibacterial Organisms Common Hospital (nosocomial) Infections Description of Infections Acinetobacter Baumannii Clostridium Difficile Gastroenteritis Hospital-Acquired Pneumonia (HAP) Pseudomonas Aeruginosa Staphylococcus Aureus/Methicillin-Resistant Staphylococcus Aureus Stenotrophomonas Maltophilia Tuberculosis Urinary Tract Infections Vancomycin-Resistant Enterococcus Hospital Units and Infection Risks Burn Units Intensive Care Units Emergency Departments Principles of Anti-bacterial Therapy Infecting Organism Antibiotic Sensitivity Testing Site of Infection Host Defenses and Organ Function Antibiotic Pharmacokinetics Monitoring Therapy General Infection Statistics Nosocomial Infection Statistics Populations at Risk for Infection Demographics of the World Infections and Drug Resistance Causes of Drug Resistance Antibiotic Abuse Antibiotic Use in Agriculture Drug Resistance in Select Populations Children
  6. 6. The Elderly Compromised Individuals Measures for Reducing Resistance Antibiotic Cycling Antibiotic Education Screening Hospitalized patients The American Recovery and Reinvestment Act of 2009 Financial Impact of Hospital Infections State Level Case Study of HAI Admissions and Readmissions Manufacturer and Marketer Trends Trends in Partnerships and Alliances Developers TrendsCHAPTER THREE: HOSPITAL INFECTION DIAGNOSTICS Overview Methods of Transmission Airborne Contact Direct-Contact Transmission Indirect-Contact Transmission Droplet Vehicle Prevention Measures Testing Drug-Resistance/Susceptibility Testing Genotypic Methods DNA Sequencing Solid-phase Hybridization Techniques Microarrays Real-time Polymerase Chain Reaction Techniques Phenotypic Methods Phage-based Assays Colorimetric Methods The Nitrate Reductase Assay Nosocomial Disease Testing Acinetobacter Baumannii Clostridium Difficile Hospital-Acquired Pneumonia Ventilator-Associated Pneumonia
  7. 7. Pseudomonas Aeruginosa Staphylococcus Aureus Tuberculosis Urinary Tract Infections New Developments Market Overview Total Market Size and Forecast HAI Testing by Infection Type Hospital Infection Testing Market by Geographical Region Molecular Testing vs. Conventional Testing. Market and Forecast for Molecular HAI Competitors in HAI TestingCHAPTER FOUR: TREATING HOSPITAL INFECTIONS Overview Treatment Guidelines Clostridium Difficile Gastroenteritis Hospital-Acquired Pneumonia Ventilator-associated Pneumonia Pseudomonas Aeruginosa Staphylococcus Aureus Stenotrophomonas maltophilia Tuberculosis Urinary Tract Infections Recent Drug Approvals Market OverviewCHAPTER FIVE: MARKET SUMMARY Market Considerations Market Overview Regional Breakdown of Market Competitive SummaryCHAPTER SIX: COMPANY PROFILES Introduction Abbott Laboratories AdvanDx, Inc. Alere AstraZeneca Bayer Healthcare Pharmaceuticals (Bayer Schering Pharma) v Becton, Dickinson
  8. 8. Cepheid Cubist Pharmaceuticals Daiichi Sankyo Diatherix Laboratories Inc. Gen-Probe Inc. GlaxoSmithKline Johnson & Johnson Merck & Co. Meridian Bioscience, Inc. Pfizer Roche Seegene, Inc.APPENDIX: LIST OF MAJOR PROVIDERS LIST OF EXHIBITSCHAPTER ONE: EXECUTIVE SUMMARY Table 1-2: The Global Market for Hospital Infections by Product Segment (Diagnostics, Treatment), 2005-2015 Figure 1-1: The Global Market for Hospital Infections 2005-2015 Figure 1-2: Growth Rate - HAI Diagnostic Market vs. HAI Treatment Market Table 1-3: MRSA Risk and Testing PriorityCHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDS Table 2-1: Antibiotics with Difficult Penetration Table 2-2: Common Nosocomial Infections Table 2-3: Risk Factors for M. tuberculosis Table 2-4: Common ICU Infections Table 2-5: Estimated World and U.S. Incidence of Bacterial Infections Figure 2-1: Estimated World and U.S. Incidence of Bacterial Infections Figure 2-2: U.S. Hospital Admissions, Percent Acquiring HAIs Table 2-6: World Population at Risk for Serious Bacterial Infections, Secondary to Chronic Diseases by Selected Geographical Region (World, U.S., Europe), 2010 Figure 2-3: World Population at Risk for Serious Bacterial Infections, Secondary to Chronic Diseases by Selected Geographical Region, 2010 Table 2-4: Estimated World Population by Age and Geographical Region, 2010 Figure 2-4: Estimated World Population by Age and Geographical Region, 2010 Table 2-5: Pennsylvania State Analysis of HAI Readmissions and Related Costs, 2009 Table 2-6: Pennsylvania State Analysis of HAIs, 2009CHAPTER THREE: HOSPITAL INFECTION DIAGNOSTICS Table 3-1: CDC Healthcare Setting Guidelines
  9. 9. Table 3-2: MRSA Risk and Testing Priority Table 3-3: Recent Approvals for Hospital Infection Testing (Product, Company, Description of Test, Approved Regions) Table 3-4: New Developments, Hospital Infection Testing (Developer, Description, Status, Indication) Table 3-5: The World Market for Hospital Infection Testing/Diagnostics 2005-2015 (Revenues, Percent Change) Figure 3-1: The World Market for Hospital Infection Testing/Diagnostics 2005-2015 Figure 3-2: Distribution of Revenues for HAI Testing by Infection Type, 2010 Estimates (MRSA, Cdiff, Other HAIs) Table 3-6: The World Market for Hospital Infection Testing/Diagnostics Estimated Products Sales by Geographic Region (US, Europe, ROW) 2005-2015 Figure 3-3: The World Market for Hospital Infection Testing/Diagnostics Estimated Product Sales by Geographic Region (US, Europe, ROW) 2005-2015 Table 3-7: Detection Time for MRSA by Screening Method (Test Type, Turnaround Time, Average Cost) Figure 3-4: Molecular vs. Conventional Diagnostic Market for HAIs in 2010 and Projected to 2015 Table 3-8: The World Market for Hospital Infection Diagnostics (Top 9 Leading Suppliers vs. Others) 2010CHAPTER FOUR: TREATING HOSPITAL INFECTIONS Table 4-1: Treatment Options for Bacterial Infections (Type, Brand, and Manufacturer) Table 4-3: Recent Approvals for Hospital Infection Treatments Table 4-5: The World Market for Hospital Infection Treatment 2005-2015 Figure 4-3: The World Market for Hospital Infection Treatment Estimated Market Share by Region, 2010CHAPTER FIVE: MARKET SUMMARY Table 5-1: The Global Market for Hospital Infections by Product Segment, 2005-2015 Figure 5-1: The Global Market for Hospital Infection Products 2005-2015 Figure 5-2: The Global Market for Hospital Infection Products by Product Segment, 2010 (Diagnostics, Treatment) Available immediately for Online Download at http://www.marketresearch.com/product/display.asp?productid=6450720 US: 800.298.5699
  10. 10. UK +44.207.256.3920Intl: +1.240.747.3093Fax: 240.747.3004

×